Dogged by AbbVie’s new share-stealing Mavyret, Gilead’s hep C forecast comes in far short

Gilead's once-high-flying hepatitis C drugs have come a long way down since their peak sales years, and the slide isn't over. Thanks to new competition from AbbVie, the Gilead franchise is looking at another rough year—and that comes amid a couple of key patent expirations.Original Article